Exculpatory Language in Informed Consent
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
August 19, 2011
July 21, 2021
b715dc6a-852a-4eb2-b7e7-6f3773d248cc
Related Documents
Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations
Guidance DocumentMarch 18, 2014Center for Drug Evaluation and Research
Investigational New Drug Applications Prepared and Submitted by Sponsor-Investigators
Guidance DocumentMay 15, 2015Center for Drug Evaluation and Research
DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers
Guidance DocumentDecember 9, 2014Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.